2023 World Conference on Lung Cancer (Posters)-EP07.01. Local Control & Toxicity Results of Stereotactic Body Radiotherapy in Central Lung Tumors

EP07.01. Local Control & Toxicity Results of Stereotactic Body Radiotherapy in Central Lung Tumors - PDF(Slides)

Pdf Summary

The study evaluated the safety and efficacy of stereotactic body radiotherapy (SBRT) for patients with centrally located primary lung tumors or lung metastases. The study included 63 patients with a total of 75 lesions. The mean age of the patients was 67, with 67% being male. The mean diameter of the lesions was 27mm and the mean volume was 10.5cc. The median follow-up period was 12 months.<br /><br />The results showed that the local control rate was 93% at 1 year and 89% at 2 years. Local recurrence was detected in 9% of the lesions during the follow-up period. Only one patient experienced grade 3 radiation pneumonitis, while 8% had grade 2 radiation pneumonitis and one of them also had grade 1 dysphagia. No patients experienced grade 4-5 toxicity.<br /><br />Based on these findings, SBRT appears to be a safe and effective treatment option for patients with centrally located primary lung tumors or lung metastases. However, the study has limitations such as a short follow-up period and a relatively small sample size. Further studies with longer follow-up periods and larger patient cohorts are needed to confirm these results and assess the long-term outcomes of treatment.

Asset Subtitle

Serap Akyürek

Meta Tag

Speaker Serap Akyürek

Topic Early-Stage NSCLC: Best Practice

Keywords

SBRT

stereotactic body radiotherapy

safety

efficacy

centrally located primary lung tumors

lung metastases

local control rate

radiation pneumonitis

dysphagia

toxicity